2021 Revenues ($USD) : $4,697,305,171 2021 Revenues (foreign currencies) : JP¥515,952,000,000 2021 R&D spend : $1,207,957,028.40 2021 Number of Employees : 3067 Fiscal Year End : 3/31/2021 Leader : CEO Hiroshi Nomura
The Osaka, Japan–based company traces its origin to the 2005 merger of Sumitomo Pharmaceuticals and Dainippon Pharmaceuticals. The company has steadily expanded since that merger, acquiring the U.S. firm Sepracor Inc. (now Sunovion) in 2009 and the oncology-focused biotech Boston Biomedical in 2012. The firm entered the field of regenerative medicine and cell therapy a year later. The company currently focuses on psychiatry and neurology, oncology and regenerative medicine/cell therapy. —BB
[Sumitomo Dainippon Pharma head office in Osaka, Japan. Image courtesy of Wikipedia.]
Tell Us What You Think!
You must be logged in to post a comment.